Combining Cancer Immunotherapy and Targeted Therapy

Overview

Journal Curr Opin Immunol

Publisher Elsevier

Specialty Allergy & Immunology

Date 2013 Apr 9

PMID 23561594

Citations 36

Authors

Antoni Ribas

Jedd D Wolchok

Affiliations

Soon will be listed here.

Abstract

The ability to pharmacologically modulate key signaling pathways that drive tumor growth and progression, but do not negatively impact the function of lymphocytes, provides avenues for rational combinatorial approaches to improve the antitumor activity of tumor immunotherapies. Novel targeted agents can very specifically block oncogenic events in cancer cells, leading to a pro-apoptotic milieu and a potential increase in sensitivity to recognition and attack by cytotoxic T lymphocytes (CTLs). Furthermore, targeted pathway modulation in lymphocytes may change their function and have activating effects in some instances. When tested together with recently developed powerful tumor immunotherapies, such combinations may exploit the highly specific targeting of oncogenes with small molecule inhibitors to lead to high frequency of tumor regressions, and merge this benefit with the durable responses achievable with effective tumor immunotherapies.

Citing Articles

Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.

Haugh A, Daud A Am J Clin Dermatol. 2024; 25(3):407-419.

PMID: 38329690 DOI: 10.1007/s40257-023-00841-0.

Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice.

Dailah H, Hommdi A, Koriri M, Algathlan E, Mohan S Heliyon. 2024; 10(2):e24559.

PMID: 38298714 PMC: 10828696. DOI: 10.1016/j.heliyon.2024.e24559.

Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.

El Zarif T, Nassar A, Adib E, Fitzgerald B, Huang J, Mouhieddine T J Clin Oncol. 2023; 41(21):3712-3723.

PMID: 37192435 PMC: 10351941. DOI: 10.1200/JCO.22.02459.

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?.

Haist M, Stege H, Kuske M, Bauer J, Klumpp A, Grabbe S Cancer Metastasis Rev. 2023; 42(2):481-505.

PMID: 37022618 PMC: 10348973. DOI: 10.1007/s10555-023-10097-z.

Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future.

Cheng Z, Du Y, Yu L, Yuan Z, Tian J Mol Imaging Biol. 2022; 24(2):264-279.

PMID: 35102468 DOI: 10.1007/s11307-021-01688-9.

References

Srivastava R, Utley A, Shrikant P . Rapamycin: A rheostat for CD8(+) T-cell-mediated tumor therapy. Oncoimmunology. 2012; 1(7):1189-1190. PMC: 3494641. DOI: 10.4161/onci.20663. View

Balachandran V, Cavnar M, Zeng S, Bamboat Z, Ocuin L, Obaid H . Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011; 17(9):1094-100. PMC: 3278279. DOI: 10.1038/nm.2438. View

Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A . Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2004; 11(1):71-6. DOI: 10.1038/nm1160. View

Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S . PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 2010; 23(2):190-200. PMC: 2848976. DOI: 10.1111/j.1755-148X.2010.00685.x. View

Johnson J, Pahuja A, Graham M, Hering B, Hancock W, Bansal-Pakala P . Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques. Transplant Proc. 2008; 40(2):459-61. PMC: 2638761. DOI: 10.1016/j.transproceed.2008.01.039. View

Setiadi A, Omilusik K, David M, Seipp R, Hartikainen J, Gopaul R . Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 2008; 68(23):9601-7. DOI: 10.1158/0008-5472.CAN-07-5270. View

Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo J . BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2012; 19(2):393-403. PMC: 4120472. DOI: 10.1158/1078-0432.CCR-12-1626. View

Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M . A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med. 2006; 12(2):214-9. DOI: 10.1038/nm1356. View

Frederick D, Piris A, Cogdill A, Cooper Z, Lezcano C, Ferrone C . BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19(5):1225-31. PMC: 3752683. DOI: 10.1158/1078-0432.CCR-12-1630. View

10.

Koya R, Mok S, Otte N, Blacketor K, Comin-Anduix B, Tumeh P . BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012; 72(16):3928-37. PMC: 3422880. DOI: 10.1158/0008-5472.CAN-11-2837. View

11.

Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni T . Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res. 2007; 13(15 Pt 1):4538-46. DOI: 10.1158/1078-0432.CCR-07-0014. View

12.

Callahan M, Rampal R, Harding J, Klimek V, Chung Y, Merghoub T . Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med. 2012; 367(24):2316-21. PMC: 3627494. DOI: 10.1056/NEJMoa1208958. View

13.

Skov S, Pedersen M, Andresen L, Straten P, Woetmann A, Odum N . Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005; 65(23):11136-45. DOI: 10.1158/0008-5472.CAN-05-0599. View

14.

Magner W, Kazim A, Stewart C, Romano M, Catalano G, Grande C . Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000; 165(12):7017-24. DOI: 10.4049/jimmunol.165.12.7017. View

15.

Wilmott J, Long G, Howle J, Haydu L, Sharma R, Thompson J . Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2011; 18(5):1386-94. DOI: 10.1158/1078-0432.CCR-11-2479. View

16.

Araki K, Turner A, Shaffer V, Gangappa S, Keller S, Bachmann M . mTOR regulates memory CD8 T-cell differentiation. Nature. 2009; 460(7251):108-12. PMC: 2710807. DOI: 10.1038/nature08155. View

17.

Tao R, de Zoeten E, Ozkaynak E, Chen C, Wang L, Porrett P . Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007; 13(11):1299-307. DOI: 10.1038/nm1652. View

18.

Li Q, Rao R, Araki K, Pollizzi K, Odunsi K, Powell J . A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity. 2011; 34(4):541-53. PMC: 3083826. DOI: 10.1016/j.immuni.2011.04.006. View

19.

Christiansen A, West A, Banks K, Haynes N, Teng M, Smyth M . Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A. 2011; 108(10):4141-6. PMC: 3054015. DOI: 10.1073/pnas.1011037108. View

20.

Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K . The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer. 2008; 122(11):2542-53. DOI: 10.1002/ijc.23407. View